{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:42:00Z","timestamp":1776231720963,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>EVI1 positivity is a well-recognized high-risk factor in acute myeloid leukemia (AML), typically characterized by complex molecular genetic abnormalities, suboptimal responses to conventional chemotherapy, and a poor prognosis. We report a case of a 42-year-old patient with EVI1-positive AML harboring the MLL-AF6 fusion gene, who failed to achieve remission after undergoing standard \u201cIA\u201d induction therapy and was then treated with VAH (venetoclax, azacitidine, and homoharringtonine) consolidation chemotherapy. The patient subsequently received all-trans retinoic acid (ATRA) (20 mg twice daily, administered orally) and achieved complete remission with incomplete hematologic recovery (CRh) after 24 days, accompanied by a marked reduction in EVI1 expression relative to baseline levels. Following this, consolidation therapy consisting of one cycle of \u201cVAH plus ATRA\u201d led to complete remission (CR). This case suggests that the combination of ATRA with the VAH regimen may demonstrate promising efficacy and an acceptable safety profile in patients with EVI1-positive AML who are refractory to conventional chemotherapy. However, further clinical studies are required to confirm its wider applicability.<\/jats:p>","DOI":"10.3389\/fonc.2026.1790087","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:42:17Z","timestamp":1776228137000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["All-trans retinoic acid combined with the VAH regimen for EVI1-positive acute myeloid leukemia: a case report with a brief literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yingxin","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Pei","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Laboratory of Hematological Diseases, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]},{"name":"Department of Clinical Pharmacy, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Hematology, Jiaozuo People\u2019s Hospital","place":["Jiaozuo, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1186\/s12887-024-05243-7","article-title":"Clinical significance of dynamic monitoring of EVI1 gene expression in pediatric acute myeloid leukemia","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Pediatr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2021.12.398","article-title":"EVI1 protein interaction dynamics: Targetable for therapeutic intervention","volume":"107","author":"Paredes","year":"2022","journal-title":"Exp Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217547","article-title":"The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression","volume":"615","author":"Ma","year":"2025","journal-title":"Cancer Lett"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712747","article-title":"High EVI1 expression predicts adverse outcomes in children with de novo acute myeloid leukemia","volume":"11","author":"Zheng","year":"2021","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1404092","article-title":"All-trans retinoic acid in hematologic disorders: Not just acute promyelocytic leukemia","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ccell.2025.03.008","article-title":"All-trans retinoic acid beyond acute promyelocytic leukemia","volume":"43","author":"Rehman","year":"2025","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s12916-024-03690-8","article-title":"Synthesizing regulatory guidance for demonstrating preclinical efficacy and translating promising cell therapies to early phase clinical trials: A scoping review","volume":"22","author":"Jeffers","year":"2024","journal-title":"BMC Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01017-7","article-title":"Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Xuan","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.897220","article-title":"Treatment options for acute myeloid leukemia patients aged <60 years","volume":"12","author":"Visani","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-653840","article-title":"Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid","volume":"127","author":"Verhagen","year":"2016","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015325","article-title":"Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia","volume":"140","author":"Tanaka","year":"2022","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.02.019","article-title":"A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia","volume":"157","author":"Gr\u00f6schel","year":"2014","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-119230","article-title":"High EVI1 levels predict adverse outcome in acute myeloid leukemia: Prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated","volume":"111","author":"Lugthart","year":"2008","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Gr\u00f6schel","year":"2010","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281337","article-title":"Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1","volume":"117","author":"Lugthart","year":"2010","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-393827","article-title":"EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs","volume":"119","author":"Bindels","year":"2012","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-234310","article-title":"Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells","volume":"117","author":"Arai","year":"2011","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12444","article-title":"High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: A report from the children\u2019s oncology group","volume":"162","author":"Ho","year":"2013","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2008.06.002","article-title":"Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells","volume":"3","author":"Goyama","year":"2008","journal-title":"Cell Stem Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2009.07398.x","article-title":"Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response","volume":"276","author":"Bingemann","year":"2009","journal-title":"FEBS J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.040535","article-title":"Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia","volume":"96","author":"V\u00e1zquez","year":"2011","journal-title":"Haematologica"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.109878","article-title":"Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a\/MYCN axis","volume":"125","author":"Cao","year":"2020","journal-title":"Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-019-0095-9","article-title":"Efficacy of all-trans-retinoic acid in high-risk acute myeloid leukemia with overexpression of EVI1","volume":"7","author":"Paubelle","year":"2019","journal-title":"Oncol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1182\/blood-2019-128551","article-title":"All-trans retinoic acid enhances the anti-leukemia effect of venetoclax on acute myeloid leukemia cells","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.21037\/atm-22-1459","article-title":"Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms","volume":"10","author":"Yuan","year":"2022","journal-title":"Ann Trans Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1390229","article-title":"Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia","volume":"61","author":"Zhou","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12967-022-03497-2","article-title":"Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia","volume":"20","author":"Wei","year":"2022","journal-title":"J Transl Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1790087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:42:27Z","timestamp":1776228147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1790087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1790087"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1790087","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1790087"}}